Equilis Te

10 x 1 dose

Suspension for injection

Active substance

Clostridium tetani (toxoid)

ATC code

QI05AB03 Clostridium

QI05AB Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

QI05A Immunologicals for horse

QI05 Immunologicals for equidae

QI Immunologicals

Species

Horses

Indications

Active immunisation of horses from 6 months of age against tetanus to prevent mortality.

Onset of immunity: 2 weeks after the primary vaccination course.

Duration of immunity:17 months after the primary vaccination course. 2 years after the first revaccination.

Dose to be administered and administration route

Intramuscular use.

Allow the vaccine to reach room temperature before use.

Vaccination schedule:

Primary vaccination course

Administer one dose (1 ml), by intramuscular injection, according to the following schedule:

Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later.

Revaccination

The first revaccination is given not later than 17 months after the primary vaccination course.

Thereafter a maximum interval of two years is recommended (see scheme).

In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later)

Concurrent active and passive immunisation (emergency vaccination)

The vaccine can be used together with Tetanus Serum for treatment of injured horses that have not been immunised against tetanus. In that case, the first dose (V1) of vaccine can be given concurrently with the appropriate prophylactic dose of Tetanus Serum at a separate injection site, using separate syringes and needles. This will lead to a passive protection against tetanus for at least 21 days after concurrent administration. The second dose of the vaccine (V2) should be administered 4 weeks later. A third vaccination with Equilis Te should be repeated at least four weeks later.

Concurrent use of Equilis Te and Tetanus Serum from MSD Animal Health may reduce active immunity against tetanus compared to horses vaccinated with Equilis Te in the absence of tetanus antitoxin serum.

Adverse reactions

Horses:

Rare

(1 to 10 animals / 10,000 animals treated):

Injection site swelling^{^[1]}, Injection site pain^{^[2]}.

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Fever^{^[3]}, Lethargy³, Inappetence³, Hypersensitivity reaction^{^[4]}.

¹ A diffuse hard or soft swelling (max. diameter 5 cm), regressing within 2 days. A local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur in very rare cases.

² Pain at the injection site may result in temporary functional discomfort (stiffness).

³ Fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, and up to 3 days in exceptional circumstances.

⁴ Including anaphylaxis (sometimes fatal). If such a reaction occurs, appropriate treatment should be administered without delay. Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product.

Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.